AlTi Global Q2 2026: Revenue Climbs 20%, Yet Material Weaknesses Linger and Cash Erodes
ALTI sits 56% above its 52-week low of $2.75.
Summary
AlTi Global's Q2 2026 filing reveals 20% revenue growth and improved Adjusted EBITDA, but unremediated material weaknesses in financial controls and a declining cash balance raise significant concerns.
Key Events · Earnings and Guidance · ALTI
-
Material Weaknesses Unremediated
As of June 30, 2026, disclosure controls and procedures remain not fully effective because material weaknesses in internal control over financial reporting persist. Remediation testing has yet to be completed by management.
-
Revenue Grows 20%
Total revenue reached $131.1 million for the six months ended June 30, 2026, up from $109.5 million in the prior year, driven by higher management fees and distributions from investments.
-
Adjusted EBITDA Improves
Adjusted EBITDA rose to $20.3 million from $17.3 million, reflecting operational efficiency gains and lower professional fees, despite higher compensation costs.
-
Net Loss Driven by Investment Write-Down
Net loss from continuing operations was $22.4 million, largely due to a $15.8 million unrealized loss on an external strategic manager investment that is winding down.
Analysis · ALTI · Finance
AlTi Global's Q2 2026 results present a mixed picture. Revenue grew 20% year-over-year to $131.1 million, and Adjusted EBITDA improved to $20.3 million, signaling operational progress. However, the company continues to grapple with unremediated material weaknesses in internal controls, and its cash position has eroded to $31.2 million from $41.2 million at year-end. A $15.8 million unrealized loss on investments, tied to a fund wind-down, pushed the bottom line to a $22.4 million net loss from continuing operations. The persistent control deficiencies and shrinking liquidity are the dominant concerns, overshadowing the top-line growth.
At the time of this filing, ALTI was trading at $4.30 on NASDAQ in the Finance sector, with a market capitalization of approximately $652M. The 52-week trading range was $2.75 to $5.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.